Top

European Journal of Nuclear Medicine and Molecular Imaging

Open Access 27-04-2024 | Review Article

Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?

Authors: Janke Kleynhans, Thomas Ebenhan, Frederik Cleeren, Mike Machaba Sathekge

Published in: European Journal of Nuclear Medicine and Molecular Imaging

Abstract

Preclinical studies are essential for effectively evaluating TAT radiopharmaceuticals. Given the current suboptimal supply chain of these radionuclides, animal studies must be refined to produce the most translatable TAT agents with the greatest clinical potential. Vector design is pivotal, emphasizing harmonious physical and biological characteristics among the vector, target, and radionuclide. The scarcity of alpha-emitting radionuclides remains a significant consideration. Actinium-225 and lead-212 appear as the most readily available radionuclides at this stage. Available animal models for researchers encompass xenografts, allografts, and PDX (patient-derived xenograft) models. Emerging strategies for imaging alpha-emitters are also briefly explored. Ultimately, preclinical research must address two critical aspects: (1) offering valuable insights into balancing safety and efficacy, and (2) providing guidance on the optimal dosing of the TAT agent.

Available only for authorised users

Bodei L, Herrmann K, Schőder H, Schott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022. https://doi.org/10.1038/s41571-022-00652-y.CrossRefPubMedPubMedCentral

Vermeulen K, Vandamme M, Bormans G, Cleeren F. Design and challenges of radiopharmaceuticals. Semin Nucl Med. 2019. https://doi.org/10.1053/j.semnuclmed.2019.07.001.CrossRefPubMed

Kunikowska J, Królicki L. Targeted ɑ-emitter therapy of neuroendocrine tumors. Semin Nucl Med. 2020. https://doi.org/10.1053/j.semnuclmed.2019.11.003.CrossRefPubMed

Hatcher-Lammare JL, Sanders VA, Rahman M, Cutler CS, Francesconi LC. Alpha emitting nuclides for targeted therapy. Nucl Med Biol. 2021. https://doi.org/10.1016/j.nucmedbio.2020.08.004.CrossRef

Daguenet E, Louati S, Wozny AS, Vial N, Gras M, Guy JB, Vallard A, Rodriguez-Lafrasse C, Magne N. Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br J Cancer. 2020. https://doi.org/10.1038/s41416-020-0942-3.CrossRefPubMedPubMedCentral

Tafreshi NK, Doligalski ML, Tichacek CJ, Pandya DN, Budzevich MM, El-Haddad G, et al. Development of targeted alpha particle therapy for solid tumors. Molecules. 2019. https://doi.org/10.3390/molecules24234314.CrossRefPubMedPubMedCentral

Kluetz PG, Pierce W, Maher VE, Zhang H, Thang S, Song P, Liu Q, et al. Radium Ra223 dichloride injection: US Food and Drug Administration drug approval summary. Clin Cancer Res. 2014. https://doi.org/10.1158/1078-0432.CCR-13-2665.CrossRefPubMed

Pouget JP, Constanzo J. Revisiting the radiobiology of targeted alpha therapy. Front Med. 2021. https://doi.org/10.3389/fmed.2021.692436.CrossRef

Echavidre W, Target D, Faraggi M, Picco V, Montemagno C. Recent pre-clinical advancements in nuclear medicine: pioneering the path to a limitless future. Cancers. 2023. https://doi.org/10.3390/cancers15194839.CrossRefPubMedPubMedCentral

10.

Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms241411626.CrossRefPubMedPubMedCentral

11.

Pallares RM, Abergel RJ. Development of radiopharmaceuticals for targeted alpha therapy: where do we stand? Front Med. 2022. https://doi.org/10.3389/fmed.2022.1020188.CrossRef

12.

ClinicalTrials.gov. 2023. URL: https://clinicaltrials.gov/. Accessed 30/11/2023.

13.

Yard BD, Gopal P, Bannik K, Siemeister G, Hagemann UB, Abazeed ME. Cellular and genetic determinants of the sensitivity of cancer to ɑ-particle irradiation. Cancer Res. 2019. https://doi.org/10.1158/0008-5472.CAN-19-0859.CrossRefPubMedPubMedCentral

14.

Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. ɑ-Emitters for Radiotherapy: from basic radiochemistry to clinical studies part 1. J Nucl Med. 2018. https://doi.org/10.2967/jnumed.116.186338.CrossRefPubMedPubMedCentral

15.

Kozempel J, Mokhodoeva O, Vlk M. Progress in targeted alpha-particle therapy. What we learned about recoils release from in vivo generators. Molecules. 2018. https://doi.org/10.3390/molecules23030581.CrossRefPubMedPubMedCentral

16.

Zhang J, Qin S, Yang M, Zhang X, Zhang S, Yu F. Alpha-emitters and targeted alpha therapy in cancer treatment. Radiology. 2023. https://doi.org/10.1002/ird3.30.CrossRefPubMedPubMedCentral

17.

Sgourous G, Hobbs RF, Abou DS, Chapter. The role of preclinical models in radiopharmaceutical therapy. American Society of Clinical Oncology Educational book. 2014 e121–5. https://doi.org/10.14694/EdBook_AM.2014.34.e121.

18.

Pomykala KL, Hadaschik BA, Sartor O, Gillessen S, Sweeney CJ, Maughan T, Hofman MS, Herrmann K. Next generation radiotheranostics promoting precision medicine. Ann Oncol. 2023. https://doi.org/10.1016/j.annonc.2023.03.00.CrossRefPubMed

19.

Nascimento ML, Farais AB, Carvalho AT, Albuquerque RF, Ribeiro LN, et al. Impact of xerostomia on the quality of life of patients submitted to head and neck radiotherapy. Med Oral Patol Oral Cir Bucal. 2019. https://doi.org/10.4317/medoral.23131.CrossRefPubMedPubMedCentral

20.

Vaidyanathan G, Mease RC, Minn Il, Choi J, Chen Y, Shallal H, Kang CM, et al. Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer. Nucl Med Biol. 2021. https://doi.org/10.1016/j.nucmedbio.2021.01.002.CrossRefPubMedPubMedCentral

21.

Lead-212 PSMA.

22.

Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, Solbach C, et al. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. Eur J Nucl Med Mol Imaging Res. 2022. https://doi.org/10.1186/s13550-022-00935-6.CrossRef

23.

Begum NJ, Glatting G, Wester HJ, Eiber M, Beer AJ, Kletting P. The effect of ligand amount, affinity and internalzation on PSMA-targeted imaging and therapy: a simulation study using a PBPK model. Sci Rep. 2019. https://doi.org/10.1038/s41598-019-56603-8.CrossRefPubMedPubMedCentral

24.

Morris M, Ulaner GA, Halperin DM, Strosberg JR, Mehr SH, Daneng L, Soares HP, Anthony LB, et al. Action phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2-expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: intital safety analysis. J Clin Oncol. 2023. https://doi.org/10.1200/JCO.2023.41.16_suppl.4132.CrossRefPubMedPubMedCentral

25.

Al-Nahhas A. Nuclear medicine imaging of neuroendocrine tumours. Clin Med. 2012. https://doi.org/10.7861/clinmedicine.12-4-377.CrossRef

26.

Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017. https://doi.org/10.2967/jnumed.116.186783.CrossRefPubMed

27.

Handula M, Beekman S, Konijnenberg M, Stuurman D, De Ridder C, Bruchertseifer F, et al. First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs. Eur J Nucl Med Mol Imaging Radiopharm Chem. 2023. https://doi.org/10.1186/s41181-023-00197-0.CrossRef

28.

Van der Heide CD, Dalm SU. Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05870-1.CrossRefPubMedPubMedCentral

29.

Aso A, Nabetani H, Matsuura Y, Kadonaga Y, Shirakami Y, Watabe T, Yoshiya T, et al. Evaluation of astatine-211 labeled fibroblast activation protein inhibitor (FAPI): comparison of different linkers with polyethylene glycol and piperazine. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24108701.CrossRefPubMedPubMedCentral

30.

Echigo H, Mishiro K, Munekane M, Fuchigami T, Washiyama K, Takahashi K, et al. Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06457-0.CrossRefPubMed

31.

Liatsou I, Josefsson A, Yu J, Li Z, Davis K, Brayton C, Wang H, et al. Early normal tissue effects and bone marrow relative biological effectiveness for actinium-225 labelled HER2/neu-targeting antibody. Int J Radiat Oncol Biol Phys. 2023. https://doi.org/10.1016/j.ijrobp.2023.06.00.CrossRefPubMed

32.

Pfannkuchen N, Bausbacher N, Pektor S, Miederer M, Rosch F. In vivo evaluation of [225Ac]Ac-DOTAZol for ɑ-therapy of bone metastases. Curr Radiopharm. 2018. https://doi.org/10.2174/1874471011666180604083911.CrossRefPubMed

33.

Garg RV, Allen KHJ, Dawicki W, Geoghegan EM, Ludwig DL, Dadachova E. 225Ac-labeled CD33 targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukaemia models. Cancer Med. 2020. https://doi.org/10.1002/cam4.3665.CrossRefPubMedPubMedCentral

34.

Makvandi M, Samanta M, Mortorano P, Lee H, Gitto SB, Patel K, Groff D, et al. Pre-clinical investigation of astatine-211 parthanatine for high-risk neuroblastoma. Commun Biol. 2022. https://doi.org/10.1038/s42003-022-04209-8.CrossRefPubMedPubMedCentral

35.

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT05557708, Phase 1 Trial of Dosimetry Guided 212Pb-pentixather Radioligand Therapy in Patients With Atypical Lung Carcinoids and Neuroendocrine Carcinomas; [cited 2023 November 18]; Available from:https://classic.clinicaltrials.gov/ct2/show/NCT05557708.

36.

Dabagian H, Taghvaee T, Martoano P, Martinez D, Samanta M, Watkins CM, Chai R, et al. PARP-targeted alpha-particle therapy enhances response to PD-1 immune-checkpoint blockade in a syngeneic mouse model of glioblastoma. ACS Pharmacol Transl Sci. 2021. https://doi.org/10.1021/acsptsci.0c00206.CrossRefPubMedPubMedCentral

37.

Targeted Alpha Therapy Working Group. Targeted alpha therapy, an emerging class of cancer agents. JAMA Oncol. 2018; https://doi.org/0.1001/jamaoncol.2018.4044.

38.

Piron S, Verhoeven J, De Coster E, Descamps B, Kersemans K, Pieters L, Vral A, Vanhove C, De Vos P. Impact of the molar activity and PSMA expression level on [18F]AlF-PSMA-11 uptake in prostate cancer. Sci Rep. 2021. https://doi.org/10.1038/s41598-021-02104-6.CrossRefPubMedPubMedCentral

39.

Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, et al. Ac-PSMA-6117 for PSMA-targeted ɑ-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;225. https://doi.org/10.2967/jnumed.116.178673.

40.

Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm. 2011. https://doi.org/10.2174/1874471011104040306.CrossRefPubMedPubMedCentral

41.

King GA, Miller WH, Bivens KR, Bond A, Glascock M, Rangaraj D, Horowitz EP, McAlister DR. Approaches to manufacturing alpha emitters for radioimmunotherapeutic drugs. AIP Con Proceed. 2003. https://doi.org/10.1063/1.1619908.CrossRef

42.

Jeong JM. Application of a small molecule radiopharmaceutical concept to improve kinetics. Nucl Med Mol Imaging. 2016; https://doi.org/0.1007/s13139-015-0369-6.

43.

Chaturvedi S, Mishra AK. Small molecule radiopharmaceuticals - a review of current approaches. Front Med. 2016. https://doi.org/10.3389/fmed.2016.00005.CrossRef

44.

Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides.Eur. J Nucl Med Mol Imaging. 2012. https://doi.org/10.1007/s00259-011-2001-z.CrossRef

45.

Davis RA, Ganguly T, Hausner SH, Sutcliffe JL. Peptides as vectors for radiopharmaceutical therapy. Radiopharm Therapy. 2023. https://doi.org/10.1007/978-3-031-39005-0_13.CrossRef

46.

Wynendaele E, Bracke N, Stalmans S, De Spiegeleer B. Development of peptide and protein based radiopharmaceuticals. Curr Pharm Des. 2014. https://doi.org/10.2174/13816128113196660663.CrossRefPubMed

47.

Chakraborty K, Mondal J, An JM, Park J, Lee YK. Advances in radionuclides and radiolabelled peptides for cancer therapeutics. Pharmaceutics. 2023. https://doi.org/10.3390/pharmaceutics15030971.CrossRefPubMedPubMedCentral

48.

Evans BJ, King AT, Katsifis A, Matesic L, Jamie JF. Methods to enhance the metabolic stability of peptide-based PET radiopharmaceuticals. Molecules. 2020. https://doi.org/10.3390/molecules25102314.CrossRefPubMedPubMedCentral

49.

Dash A, Charkaborty S, Pillai MRA, Knapp FFR. Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm. 2015. https://doi.org/10.1089/cbr.2014.1741.CrossRefPubMed

50.

Gharibkandi NA, Conlon JM, Hosseinimehr SJ. Strategies for improving stability and pharmacokinetic characteristics of radiolabeled peptides for imaging and therapy. Peptides. 2020. https://doi.org/10.1016/j.peptides.2020.170385.CrossRef

51.

Park EA, Graves SA, Menda Y. The impact of radiopharmaceutical therapy on renal function. Semin Nucl Med. 2022. https://doi.org/10.1053/j.semnuclmed.2022.02.004.CrossRefPubMed

52.

Kartochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgernstern A, Haberkorn U, Giesel FL. Targeted alpha therapy of mCRPC: dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-017-3817-y.CrossRef

53.

Cassels I, Ahenkorah S, Burgoyne AR, Van de Voorde M, Deroose CM, Cardinaels T, Bormans G, Ooms M, Cleeren F. Radiolabeling of human serum albumin with terbium-161 using mild conditions and evaluation of in vivo stability. Front Med. 2021. https://doi.org/10.3389/fmed.2021.675122.CrossRef

54.

Lin M, Paolillo V, Le DB, Macapinlac H, Ravizzini G. Monoclonal antibody based radiopharmaceuticals for imaging and therapy. Curr Probl Cancer. 2021. https://doi.org/10.1016/j.currproblcancer.2021.100796.CrossRefPubMed

55.

Carter LM, Poty S, Sharma SK, Lewis JS. Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy - model, vector and radionuclide selection. J Label Compd Rad. 2018. https://doi.org/10.1002/jlcr.3612.CrossRef

56.

Carlin S. Penetrating the barriers to successful ɑ-radioimmunotherapy. J Nucl Med. 2018. https://doi.org/10.2967/jnumed.117.205146.CrossRefPubMed

57.

Moek KL, Giesen D, Kok IC, De Groot DJA, Jalving M, Fehrmann RSN, Lub-de Hooge MN, Brouwers AH, De Vries E. Theranostics using antibodies and antibody-related therapeutics. J Nucl Med. 2017. https://doi.org/10.2967/jnumed.116.186940.CrossRefPubMed

58.

Seoane DC, De Saint-Hubert M, Crabbe M, Struelens L, Koole M. Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225. Q J Nucl Med Mol Imaging. 2020. https://doi.org/10.23736/S1824-4785.20.03266-5.CrossRef

59.

Gosewich A, Schelske M, Gildehaus FJ, Berg I, Kaiser L, Brosch J, Bartenstein P, Todica A, Ilhan H, Boning G. Imaged-based dosimetry for 225Ac-PSMA I&T therapy using quantitative SPECT. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-020-05024-1.CrossRef

60.

Tsai WTK, Wu A. Aligning physics and physiology: engineering antibodies for radionuclide delivery. J Label Compd Radiopharm. 2018. https://doi.org/10.1002/jlcr.3622.CrossRef

61.

Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, Veach DR, Bell M, et al. Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors – safety at curative doses. Theranostics. 2020. https://doi.org/10.7150/thno.48810.CrossRefPubMedPubMedCentral

62.

Poty S, Carter LM, Mandleywala K, Membreno R, Abdel-Atti D, Ragupathi A, Scholz WW, Zeglis BM, Lewis JS. Leveraging biorthogonal click chemistry to improve 225Ac-radioimmunotehrapy of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019. https://doi.org/10.1158/1078-0432.CCR-18-1650.CrossRefPubMed

63.

Funeh CN, Asiabi P, D’Huyvetter M, Devoogdt N, Chapter. Case study #3: antibody fragments in radiopharmaceutical therapy. In: Bodei L, Lewis JS, Zeglis BM, editors Radiopharmaceutical Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-39005-0_12.

64.

Rodriguez C, Delaney S, Sarrett SM, Keinanen OM, Zeglis BM. Antibody engineering in nuclear imaging and radioimmunotherapy. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.122.263861.CrossRefPubMedPubMedCentral

65.

Funeh CN, Bridoux J, Ertveldt T, De Groof TWM, Chigoho DM, Asiabi P, Covens P, D’Huyvetter M, Devoogdt N. Optimizing the safety and efficacy of biopharmaceuticals for cancer therapy. Pharmaceutics. 2023. https://doi.org/10.3390/pharmaceutics15051378.CrossRefPubMedPubMedCentral

66.

Ostuni E, Taylor MR. Commercial and business aspects of alpha radioligand therapeutics. Front Med. 2023. https://doi.org/10.3389/fmed.2022.1070497.CrossRef

67.

Nelson BJB, Andersson JD, Wuest F. Targeted alpha therapy: progress in radionuclide production, radiochemistry and applications. Pharmaceutics. 2020. https://doi.org/10.3390/pharmaceutics13010049.CrossRefPubMedPubMedCentral

68.

Eychenne R, Cherel M, Haddad F, Guerard F, Gestin JF. Overview of the most promising radionuclides for targeted alpha therapy: the hopeful eight. Pharmaceutics. 2021. https://doi.org/10.3390/pharmaceutics13060906.CrossRefPubMedPubMedCentral

69.

Radchenko V, Morgenstern A, Jalilian AR, Famogida CF, Cutler C, Duchemin C, Hoehr C, Haddad F, Bruchertseifer F, Gausemel H, et al. Production and supply of ɑ-particle-emitting radionuclides for targeted ɑ-therapy. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.120.261016.CrossRefPubMedPubMedCentral

70.

Zimmermann R. Is actinium really happening? J Nucl Med. 2023. https://doi.org/10.2967/jnumed.123.265907.CrossRefPubMed

71.

Kleynhans J, Duatti A. The determination of the radiochemical purity of actinium-225 radiopharmaceuticals: a conundrum. Eur J Nucl Med Mol Imaging Radiopharm Chem. 2022. https://doi.org/10.1186/s41181-022-00175-y.CrossRef

72.

Morgenstern A, Apostolidis C, Bruchertseifer F. Supply and clinical application of actinium-225 and bismuth-213. Semin Nucl Med. 2020. https://doi.org/10.1053/j.semnuclmed.2020.02.003.CrossRefPubMedPubMedCentral

73.

Bal CS, Arora G. Chapter 26: theranostic in glioblastoma. IN: new insights into glioblastoma. Pages. 2023;613–30. https://doi.org/10.1016/B978-0-323-99873-4.00021-9.

74.

Anhenkorah S, Cassels I, Deroose CM, Cardinaels T, Burgoyne AR, Bormans G, Ooms M, Cleeren F. Bismuth-213 for targeted radionuclide therapy: from atom to bedside. Pharmaceutics. 2021. https://doi.org/10.3390/pharmaceutics13050599.CrossRef

75.

Guerard F, Gestin JF, Brechbiel MW. Production of [211At]astatinated radiopharmaceuticals and applications in targeted ɑ-particle therapy. Cancer Biother Radiopharm. 2013. https://doi.org/10.1089/cbr.2012.1292.CrossRefPubMedPubMedCentral

76.

Muller C, Vermeulen C, Koster U, Johnston K, Turler A, Schibili R, Van der Meulen NP. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. Eur J Nucl Med Mol Imaging Radiopharm Chem. 2017. https://doi.org/10.1186/s41181-016-0008-2.CrossRef

77.

Kokov KV, Egorova BV, German MN, Klabukov ID, Krashenninnkov ME, Larkin-Konrdov AA, Makoveeva KA, Ocvhinnikov MV, et al. 212Pb: production approaches and targeted therapy applications. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14010189.CrossRefPubMedPubMedCentral

78.

Hagemann UB, Wickstroem K, Hammer S, Bjerke RM, Zitzmann-kolbe S, Ryan OB, Karlsson J, et al. Advances in precision oncology: targeted thorium-227 conjugates as a new modality in targeted alpha therapy. Cancer Biotherapy Radiopharm. 2020. https://doi.org/10.1089/cbr.2020.3568.CrossRef

79.

Frantellizzi V, Cosma L, Brunotti G, Pani A, Spanu A, Nuvoli S, De Cirstofaro F, Civitelli L, De Vincentis G. Targeted alpha therapy with thorium-227. Cancer Biotherapy Radiopharm. 2020. https://doi.org/10.1089/cbr.2019.3105.CrossRef

80.

Murray I, Rojas B, Gear J, Callister R, Cleton A, Flux GD. Quantitative dual-isotope planar imaging of thorium-227 and radium-223 using defined energy windows. Cancer Biotherapy Radiopharm. 2020. https://doi.org/10.1089/cbr.2019.3554.CrossRef

81.

Abou DS, Thiele NA, Gutche NT, Villmer A, Zhang H, Woods JJ, Baidoo KE, Escorcia FE, Wilson JJ, Thorek DLJ. Towards the stable chelation of radium for biomedical applications with 18-membered marocyclic ligand. Chem Sci. 2021. https://doi.org/10.1039/D0SC06867E.CrossRefPubMedPubMedCentral

82.

Bruland OS, Jonasdottir TJ, Fischer DR, Larsen RH. Radium-223: from radiochemical development to clinical applications in targeted cancer therapy. Curr Radiopharm. 2008. https://doi.org/10.2174/1874471010801030203.CrossRef

83.

Shuchankova P, Kukleva E, Stamberg K, Nykl P, Sakmar M, Vlk M, Kozempel J. Determination, modelling and evaluation of kinetics of 223Ra sorption on hydroxyapatite and titanium dioxide nanoparticles. Materials. 2020. https://doi.org/10.3390/ma13081915.CrossRef

84.

Souza BNRF, Riberio ERGR, De Barros AOS, Pijeira MSO, Kenup-Hernandes HO, RiccJunior E, Filho JFSD, Dos Santos CC, et al. Nanomicelles of radium dichloride [223Ra]RaCl2 co-loaded with radioactive gold [198Au]Au-nanoparticles for targeted alpha-beta radionuclide therapy of osteosarcoma. Polymers. 2022. https://doi.org/10.3390/polym14071405.CrossRefPubMedPubMedCentral

85.

Hackam DG, Redelmeier DA. Translation of research evidence from animal to humans. JAMA. 2006. https://doi.org/10.1001/jama.296.14.1731.CrossRefPubMed

86.

Ledford H. Translational research: 4 ways to fix the clinical trial. Nature. 2011. https://doi.org/10.1038/477526a.CrossRefPubMed

87.

Bolcaen J, Kleynhans J, Nair S, Verhoeven J, Goethals I, Sathekge M, Vandevoorde C, Ebenhan T. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma. Theranostics. 2021. https://doi.org/10.7150/thno.56639.CrossRefPubMedPubMedCentral

88.

Landgraf M, Mcgovern JA, Friedl P, Hutmacher DW. Rational design of mouse models for cancer research. Trends Biotechnol. 2018. https://doi.org/10.1016/j.tibtech.2017.12.001.CrossRefPubMed

89.

Fang Z, Li P, Du F, Shang L, Li L. The role of organoids in cancer research. Exp Hematol Oncol. 2023. https://doi.org/10.1186/s40164-023-00433-y.CrossRefPubMedPubMedCentral

90.

Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023. https://doi.org/10.1038/s41392-023-01419-2.CrossRefPubMedPubMedCentral

91.

Rosfjord E, Lucas J, Li G, Gerber HP. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol. 2014. https://doi.org/10.1016/j.bcp.2014.06.008.CrossRefPubMed

92.

Lakes AL, An DD, Gaunt SS, Ansoborlo C, Liang BH, Rees JA, McKnight KD, Karsunky H, Abergel RJ. Evaluating 225Ac and 177Lu radioimmunoconjugates against antibody-drug conjugates for small-cell lung cancer. Mol Pharm. 2020. https://doi.org/10.1021/acs.molpharmaceut.0c00703.CrossRefPubMed

93.

Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S, Egusa EA, Peter R, et al. Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy. Clin Cancer Res. 2023. https://doi.org/10.1158/1078-0432.CCR-22-3291.CrossRefPubMedPubMedCentral

94.

Hammer S, Hageman UB, Zitzman-Kolbe S, Larsen A, Ellingsen C, Geraudie S, Grant D, Indrevoll B, et al. Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer. Clin Cancer Res. 2020. https://doi.org/10.1158/1078-0432.CCR-19-2268.CrossRefPubMed

95.

Duan H, Iagaru A, Aparici CM. Radiotheranostics - precision medicine in nuclear medicine and molecular imaging. Nanotheranostics. 2022. https://doi.org/10.7150/ntno.64141.CrossRefPubMedPubMedCentral

96.

Liatsou I, Josefsson A, Yu J, Li Z, Davis K, Brayton C, Wang H, Hobbs RF, Sgouros G. Early normal tissue effects and bone marrow relative biological effectiveness for an actinium-225-labeled HER2/neu-targeting antibody. Int J Radiat Oncol Biol Phys. 2023. https://doi.org/10.1016/j.ijrobp.2023.06.003.CrossRefPubMed

97.

De Veirman K, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E, Hose D, Goyvaert C, et al. CS-1 specific single-domain antibodies labeled with actinium-225 prolong survival and increase CD8 + T cells and PD-L1 expression in multiple myeloma. Oncoimmunolog. 2021. https://doi.org/10.1080/2162402X.2021.2000699.CrossRef

98.

Malo M, Allen KJH, Jiao R, Frank C, Rickles D, Dadachova E. Mechanistic insights into synergy between melanin-targeting radioimmunotherapy and immunotherapy in experimental melanoma. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21228721.CrossRefPubMedPubMedCentral

99.

Prasad A, Nair R, Bhatavdekar O, Howe A, Salerno D, Sempkowski M, Josefsson A, et al. Transport-driven engineering of liposomes for delivery of ɑ-particle radiotherapy to solid tumors: effect on inhibition of tumor progression and onset delay of spontaneous metastases. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05406-z.CrossRefPubMed

100.

Budach W, Hartford A, Gioioso D, Freeman J, Taghian A, Suit HD. Tumours arising in SCID mice share enhanced radiation sensitivity of SCID Normal tissues. Cancer Res. 1992;52(22):6292–6.PubMed

101.

Du Y, Cortez A, Josefsson A, Zarisfi M, Krimins R, Liapi E, Nedrow JR. Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma. PLoS ONE. 2022. https://doi.org/10.1371/journal.pone.0261982.CrossRefPubMedPubMedCentral

102.

Kaneda-Nakashijma K, Zhang Z, Manabe Y, Shimoyama A, Kabayama K, Watabe T, Kanai Y, Ooe K, et al. ɑ-emitting cancer therapy using 211At-AAMT targeting LAT1. Cancer Sci. 2021. https://doi.org/10.1111/cas.14761.CrossRef

103.

Kvassheim M, Revheim MER, Stokke C. Quantitative SPECT/CT imaging of lead-212: a phantom study. EJNMMI Phys. 2022. https://doi.org/10.1886/s40658-022-00481-z.CrossRefPubMedPubMedCentral

104.

FDA. Guidance document: oncology therapeutic radiopharmaceuticals: nonclinical studies and labelling recommendations guidance for industry. FDA-2018-D1772.

105.

Breeman WAP, De Jong M, Kwekkeboom DJ, Valkerna R, Bakker WH, Kooij PPM, Visser TJ, Krenning EP. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001. https://doi.org/10.1007/s002590100502.CrossRefPubMed

106.

Koziorowski J, Behe M, Decristoforor C, Ballinger J, Elsinga P, Ferrari V, Peitl PK, Todde S, Mindt TL. Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals. Eur J Nucl Med Mol Imaging Radiopharm Chem. 2017. https://doi.org/10.1186/s41181-016-004-6.CrossRef

107.

Kleynhans J, Grobler AF, Ebenhan T, Sathekge MM, Zeevaart JR. Radiopharmaceutical enhancement by drug delivery systems: a review. J Control Release. 2018. https://doi.org/10.1016/j.jconrel.2018.08.008.CrossRefPubMed

108.

Kleynhans J, Sathekge M, Ebenhan T. Obstacles, and recommendations for clinical translation of nanoparticle system-based targeted alpha-particle therapy. Materials. 2021. https://doi.org/10.3390/ma14174784.CrossRefPubMedPubMedCentral

109.

Trujillo-Nolasco M, Morales-Avila E, Cruz-Nova P, Katti KV, Ocampo-Garcia B. Nanoradiopharmaceuticals based on alpha emitters: recent development for medical applications. Pharmaceutics. 2021. https://doi.org/10.3390/pharmaceutics13081123.CrossRefPubMedPubMedCentral

110.

Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, Debus J, Marme F, et al. Development of fibroblast activation protein targeted radiotracers with improved tumor retention. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.118.224469.CrossRefPubMedPubMedCentral

111.

Garrow AA, Andrews JPM, Gonzalez ZN, Corral CA, Portal C, Morgan TEF, Walton T, Wilson I, Newby DE, Lucatelli C, Tavares AAS. Preclinical dosimetry models and the prediction of clinical doses of novel positron emission tomography radiotracers. Sci Rep. 2020. https://doi.org/10.1038/s41598-020-72830-w.CrossRefPubMedPubMedCentral

Title: Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?
Authors: Janke Kleynhans
Thomas Ebenhan
Frederik Cleeren
Mike Machaba Sathekge
Publication date: 27-04-2024
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06719-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content